open access

Vol 6, No 1 (2009)
Research paper
Published online: 2009-03-17
Get Citation

The prevalence of metabolic syndrome and cigarette smoking in patients with schizophrenia or schizophrenia-like disorders - preliminary report

Adam Wysokiński, Antoni Florkowski
Psychiatria 2009;6(1):26-35.

open access

Vol 6, No 1 (2009)
Prace oryginalne - nadesłane
Published online: 2009-03-17

Abstract


Introduction.Metabolic syndrome is a complex of abdominal obesity, hypercholesterolemia, hyperlipidemia, hypertension and abnormal blood glucose levels. The presence of this syndrome increases the risk of death due to cardio-vascular diseases. Current researches indicate that the prevalence of this syndrome may be higher in patients treated with antipsychotics comparing to general population. The objective of this paper is to evaluate the prevalence of metabolic syndrome, its components and cigarette smoking among the patients with schizophrenia or schizophrenia-like psychoses treated with antipsychotics.
Material and methods. Thirty patients were enrolled in the study (7 women and 23 men). The following data were acquired: total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides and glucose blood levels, hypertension, abdominal obesity, body weight, BMI, cigarette smoking and certain demographic factors.
Results. Metabolic syndrome was diagnosed in 43,3% of the patients (42,9% women and 43,7% men). The incidence of its components was: 76,7% (abdominal obesity), 43,3% (hipertriglicerydemia), 46,7% (decreased HDL cholesterol blood level), 26,7% (hypertension), 20,0% (impaired fasting glucose). Abnormal body weight (overweight or obesity) was found in 80% of the patients.
Conclusions. Achieved results confirm that metabolic syndrome is significantly more common among the patients treated with antipsychotics comparing to general population. A very high incidence of cigarette smoking and abnormal body weight was found.

Abstract


Introduction.Metabolic syndrome is a complex of abdominal obesity, hypercholesterolemia, hyperlipidemia, hypertension and abnormal blood glucose levels. The presence of this syndrome increases the risk of death due to cardio-vascular diseases. Current researches indicate that the prevalence of this syndrome may be higher in patients treated with antipsychotics comparing to general population. The objective of this paper is to evaluate the prevalence of metabolic syndrome, its components and cigarette smoking among the patients with schizophrenia or schizophrenia-like psychoses treated with antipsychotics.
Material and methods. Thirty patients were enrolled in the study (7 women and 23 men). The following data were acquired: total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides and glucose blood levels, hypertension, abdominal obesity, body weight, BMI, cigarette smoking and certain demographic factors.
Results. Metabolic syndrome was diagnosed in 43,3% of the patients (42,9% women and 43,7% men). The incidence of its components was: 76,7% (abdominal obesity), 43,3% (hipertriglicerydemia), 46,7% (decreased HDL cholesterol blood level), 26,7% (hypertension), 20,0% (impaired fasting glucose). Abnormal body weight (overweight or obesity) was found in 80% of the patients.
Conclusions. Achieved results confirm that metabolic syndrome is significantly more common among the patients treated with antipsychotics comparing to general population. A very high incidence of cigarette smoking and abnormal body weight was found.
Get Citation

Keywords

metabolic syndrome; schizophrenia; antipsychotics

About this article
Title

The prevalence of metabolic syndrome and cigarette smoking in patients with schizophrenia or schizophrenia-like disorders - preliminary report

Journal

Psychiatria (Psychiatry)

Issue

Vol 6, No 1 (2009)

Article type

Research paper

Pages

26-35

Published online

2009-03-17

Bibliographic record

Psychiatria 2009;6(1):26-35.

Keywords

metabolic syndrome
schizophrenia
antipsychotics

Authors

Adam Wysokiński
Antoni Florkowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl